TrioBiotics Pharma AG
Triton BioPharma to be profiled in Business News segment for broadcast on CNBC Europe
Triton Biopharma AG / Miscellaneous Release of a Corporate News, transmitted by DGAP - a company of EquityStory AG. The issuer / publisher is solely responsible for the content of this announcement. ---------------------------------------------------------------------- Triton BioPharma to be profiled in Business News segment for broadcast on CNBC Europe Zug, Switzerland – January 20th 2009 – TRITON BIOPHARMA AG (Frankfurt: 4ON) today announced that the company will be profiled in an interview by Business News Television scheduled to air on CNBC Europe on January 21, 2009, during the Squawk Box Europe/Power Lunch between 12pm and 2pm GMT. The broadcast identifies exciting and innovative companies in the field of science and technology, highlighting Triton’s unique pharmaceutical development pipeline and aggressive management team. Focused on the biodiversity of marine natural products as a source of drug leads, the interview provides an overview of Triton’s business model, targeted areas of research and its commitment to collaboration with leading academic institutions and investigators worldwide. Triton has been able to create a critical mass of highly qualified scientific and business development expertise. This has been accomplished by engaging global experts in each of their particular fields. This international scientific and business team is absolutely committed to advancing its drug development portfolio targeting drug resistant infectious diseases, cancer and neurological disorders. 'Triton was established as a vehicle to support commercialization of valuable drug discovery and preclinical research conducted by top research facilities and investigators worldwide', said Angelo Boujos, Chairman and CEO of Triton BioPharma AG. Mr. Boujos continued, 'We believe that Triton is positioned perfectly to turn the recent economic downturn into tremendous opportunities to add value to its impressive product development pipeline.' 'I could not possibly be more enthusiastic about the scientific team Triton has been successful in assembling', said Mark Hamann, CSO and Director of Triton BioPharma AG. Professor Hamann continued, 'Triton has been able to attract world class scientific and business leadership through a project pipeline that is rich in pharmaceutical innovation.' About Triton BioPharma AG Triton BioPharma AG is a holding company and is only active through its wholly-owned subsidiaries, Triton BioPharma SARL and Triton BioPharma LLC. These subsidiary companies are responsible for all of Triton’s biotechnology operations and R&D activities in the discovery, development, and commercialization of novel drug leads from marine sources for the global market. With a commitment to cooperation in innovation, Triton brings together a significant network of international collaborators, consultants and industry specialists in the areas of microbiology, pharmacology, synthetic and organic chemistry, marine natural products and biochemistry. Accessing this critical mass of scientific experts and utilizing research facilities worldwide is a principal component of its drug discovery and development strategy. Triton’s current pipeline includes advanced preclinical candidates in the treatment of neuropsychiatric disorders, including depression and anxiety, inflammation, infectious diseases and cancer. The company was founded in 2008 and has its corporate office in Toronto, Canada. For more information, visit www.tritonbiopharma.com. Contact: Investor Relations Europe: Milestone Media AG, Zug (Switzerland) Phone: +41 (0) 41 5000 769 Fax: +41 (0) 41 5000 728 E-mail: info@milestonemedia.ch 20.01.2009 Financial News transmitted by DGAP ----------------------------------------------------------------------
Aktuelle News
Aktuelle Berichte
Keine Berichte gefunden
Anstehende Events
Keine Events gefunden
Webcasts
Keine Webcasts gefunden